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Although hematopoietic stem cell transplantation (HSCT) offers curative potential for beta-thalassemia major
(beta-TM), it is associated with a variable but signiﬁcant incidence of graft rejection. We studied the French
national experience for improvement over time and the potential beneﬁt of antithymocyte globulin (ATG).
Between December 1985 and December 2007, 108 patients with beta-TM underwent HSCT in 21 different
French transplantation centers. The majority of patients received a matched sibling transplant (n ¼ 96) and
a busulfan- and cyclophosphamide-based conditioning regimen (n ¼ 95), also with ATG in 57 cases. Ninety-
ﬁve of the 108 patients survived, with a median follow-up of 12 years. Probabilities of 15-year survival and
thalassemia-free survival after ﬁrst HSCT were 86.8% and 69.4%, respectively. Graft failure occurred in 24
patients, 11 of whom underwent a second HSCT. The use of ATG was associated with a decrease in rejection
rate from 35% to 10%. Thalassemia-free survival improved signiﬁcantly with time, reaching 83% in the 54
patients undergoing HSCT after 1994 (median time of HSCT). In view of the increased risk of graft rejection
after matched sibling HSCT, current French national guidelines recommend, for all children at risk for beta-
TM, the systematic addition of ATG to the myeloablative conditioning regimen and special attention to
optimize transfusion and chelation therapy in the pretransplantation period.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
Beta-thalassemia major (beta-TM) is a genetic disorder
resulting in absent or reduced b-globin chain synthesis,
causing hemolytic anemia and ineffective erythropoiesis,
with massive erythroid hyperplasia in the bone marrow andedgments on page 67.
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long RBC transfusions and iron chelation therapy has
dramatically improved patient survival over the past 4
decades [1]. Both life expectancy and quality of life with this
supportive therapy remain impaired, however. Despite the
recent promising results of gene therapy [2], in clinical
practice allogeneic hematopoietic stem cell transplantation
(HSCT) remains the sole curative option and is largely per-
formed worldwide in patients with an HLA-identical sibling
donor.
The Pesaro group in Italy ﬁrst demonstrated associations
between transplantation-related mortality and graft failureTransplantation.
Table 1
Patient, Donor, and First HSCT Characteristics
Number of patients 108
Sex, n (%)
Male 56 (52)
Female 52 (48)
Age at transplantation, years, median (range) 6.2 (0.7-32)
18 years 11 (10)
2 years 15 (14)
Recipient CMV status, n (%)
Positive 75 (72)
Negative 29
NA 4
Type of donor, n (%)
MSD 96 (89)
Matched other related 6
URD 6
Stem cell source, n (%)
Bone marrow 96 (89)
Cord blood 9 (1 combined
with BM)
Peripheral blood stem cells 3
Donor age, years, median (range) 9.5 (5-63)
Conditioning regimen, n (%)
Busulfan þ cyclophosphamide 95 (88)
Busulfan þ ﬂudarabine, with or without thiotepa 8
Total body irradiation/thoracoabdominal irradiation 5
Use of ATG, n (%)
Yes 57 (54)
No 49 (46)
NA 2
GVHD prophylaxis, n (%)
Cyclosporine A 31 (29)
Cyclosporine A þ methotrexate 64 (59)
Cyclosporine A þ mycophenolate mofetil 1
Cyclosporine A þ corticosteroid 9
T cell depletion 3
Nucleated cell dose, 108/kg, median (range)* 3.3 (0.7-11.9)
NA indicates not available.
* For BMT without T cell depletion, data are available for only 72 of 93
patients.
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infections [3,4]. The group correlated transplantation
outcome with 3 risk categories (Pesaro classes 1-3) based on
3 established severity criteria: hepatomegaly >2 cm, portal
ﬁbrosis of any degree, and inadequate compliance with
deferoxamine regimen [3,4]. The HCST therapeutic approach
pioneered by the Pesaro group is now applied worldwide.
Since the early 1990s, between 130 and 200 HSCTs per
year for thalassemia have been registered by the European
Group for Blood and Marrow Transplantation [5]. Numerous
patient series and national experiences reported outside
Italy have conﬁrmed that the majority of children under-
going HSCT from an HLA-identical sibling can be cured
of thalassemia [6-12]. Nonetheless, comparatively worse
thalassemia-free survival (TFS) was often reported, especially
at the start of transplantation programs [6]. Two important
factors that might contribute to poorer outcome are inade-
quate disease treatment before HSCT and unreliable pre-
transplantation risk status assessment.
Beta-TM is rare in France, most often seen in migrants
from south Europe and north Africa. According to the
recently established French national thalassemia registry,
approximately 350 individuals are currently living with beta-
TM in France [13]. A French bone marrow transplantation
(BMT) program for patients with beta-TM was initiated soon
after the ﬁrst genoidentical transplantations reported by the
Pesaro group. The present study retrospectively analyzed the
results of the national BMT program from its inception in
1985 to 2007. A total of 108 consecutive patients with beta-TM who underwent HSCT were included, 90% of whom
received an HLA-identical matched sibling donor (MSD)
graft. Because we initially and unexpectedly experienced
a high rate of graft rejection, we progressively added
antithymocyte globulin (ATG) to the myeloablative regimen.
Outcomes have improved markedly in recent years, with an
83% TFS rate among the patients undergoing HSCT after 1994
(median date of all transplantations). Based on our evalua-
tion of the beneﬁt of ATG in preventing graft failure, and
pending a better understanding of the mechanisms that lead
to graft failure in the setting of beta-TM, we believe that ATG
should be considered in addition to myeloablative condi-
tioning in these patients.
PATIENTS AND METHODS
Exhaustive identiﬁcation of patients was attempted through the
PROMISE European software, recording BMT data and the French thalas-
semia registry. Between December 1985 (the date of the ﬁrst HSCT regis-
tered in France) and December 2007, a total of 108 patients with beta-TM
major underwent HSCT in 21 different French transplantation centers.
Charts of study patients were analyzed retrospectively through 2 profes-
sional networks: clinicians of the French Society of Stem Cell Trans-
plantation and Cellular Therapy and the French thalassemia registry.
Informed consent was obtained from all patients or their parents for
inclusion in both the French registry and the European HSCT database. Data
were collected between September 2009 and June 2010, and analysis was
performed in September 2010. All survivors had at least 2 years of follow-up
after HSCT.
Patient Characteristics
Recipient and donor characteristics are summarized in Table 1. The
median age at the time of transplantation was 6.2 years (range, 0.7-32
years). Only 11 patients were adults age >18 years, and 15 were very young
children who underwent transplantation at age 2 years.
Patients were retrospectively stratiﬁed as much as possible according to
the Pesaro risk factors: presence of hepatomegaly >2 cm below the costal
margin; presence of portal ﬁbrosis on liver biopsy; iron chelation therapy
with deferoxamine initiated within 18 months after the ﬁrst transfusion and
administered s.c. at least 5 days/week. However, liver biopsy specimens
were obtained in only 42% of the patients, and reliable assessment of the
quality of pretransplantation iron chelation was not always available in this
retrospective study. Of the 45 recipients who underwent liver biopsy before
transplantation, 15 exhibited histological evidence of portal ﬁbrosis. Among
the patients who did not undergo liver biopsy, those age <2 years or
undergoing transplantation within the year after the ﬁrst transfusion were
considered free of ﬁbrosis.
The patients were assigned into 5 risk categories: class 1 (22 patients),
class 1 or 2 (24 patients), class 2 (49 patients), class 2 or 3 (8 patients), and
class 3 (5 patients). Twenty-seven patients had undergone splenectomy
before transplantation. At the time of transplantation, serum ferritin values
were available for 81 patients, ranging from 80 to 5900 ng/mL (median,1400
ng/mL). At transplantation or/and at the last evaluation, 86 patients were
negative and 14 were positive for hepatitis C virus antibodies. Four patients
who died before the availability of hepatitis C virus testing were not
investigated, and hepatitis C status was unknown for 4 other patients. More
than one-half (54%) of the related donors were heterozygous for beta-TM.
Transplantation Procedure
Details on conditioning regimens and graft-versus-host disease (GVHD)
prophylaxis are provided in Table 1. All patients received a myeloablative
conditioning regimen, most (95 of 108) with oral busulfan (n ¼ 72) or i.v.
busulfan (n¼ 23) combinedwith cyclophosphamide (200mg/kg total dose).
The remaining 8 patients, all treated after 2004, received ﬂudarabine, 7 in
combination with busulfan and thiotepa. In the ﬁrst years of the program,
5 patients received conditioning including irradiation (5 or 6 cGy thor-
acoabdominal irradiation or total body irradiation). Owing to the numerous
rejections occurring in recipients of ﬁrst HSCT, ATGwas introduced and used
increasingly over time in association with busulfan and cyclophosphamide
to facilitate engraftment. Fifty-seven patients received ATG as part of
conditioning. Before April 1994 (the median date of HSCT in this study), only
17 of 54 patients (31%) received ATG, compared with 40 of 54 (74%) after
1994. ATG was used systematically in all 6 patients receiving an unrelated
donor (URD) transplant.
The stem cell source was bone marrow in 96 patients, peripheral blood
stem cells in 3 patients, cord blood in 8 patients, and combined cord blood
Figure 1. Actuarial 15-year probabilities of OS, TFS, and graft failure after ﬁrst
HSCT in all patients.
Table 2
Univariate Analysis of TFS after First Transplantation
Number
of Events
% (95% CI) P Value
Year of transplantation .001
1985-1994 54 55.6 (48.1-62.9)
1994-2007 54 83.3 (74.1-90.5)
Age at transplantation .266
2 years 15 53.3 (39.9-66.5)
2-8 years 82 73.2 (65.8-79.8)
18 years 11 63.6 (45-80.3)
Splenectomy .089
Yes 27 85.2 (72.3-94.6)
No 78 66.7 (59.3-73.3)
Type of transplant .003
MSD 96 74.0 (67.1-80.1)
Other 12 33.3 (24.8-42.4)
Donor thalassemia status .40
Heterozygote 51 74.5 (65.1-82.8)
Thalassemia-free 44 68.2 (58.2-77)
Recipient CMV status .70
Positive 75 69.3 (61.9-76.2)
Negative 29 72.4 (60-83.3)
Pesaro class <.001
1 22 81.8 (67.1-92.9)
1 or 2 24 75 (60.5-86.3)
2 49 73.5 (64-82)
2 or 3 8 25.0 (17.9-32.8)
3 5 20.0 (13.5-27.4)
Use of ATG .002
Yes 57 82.5 (9.9)
No 49 55.1 (13.9)
C. Galambrun et al. / Biol Blood Marrow Transplant 19 (2013) 62e6864and bone marrow from the same sibling donor in 1 patient. The majority of
transplants (96 of 108) and all cord blood transplants (9 of 9) were from an
HLA-MSD. Six patients received a transplant from a phenotypic HLA-
identical parent or relative, and 6 others received a transplant from
a matched URD.
In the majority of patients (88%), GVHD prophylaxis consisted of
cyclosporine A alone (31 patients) or a combination of cyclosporine A and
methotrexate (64 patients). In 7 of 9 cord blood recipients, GVHD prophy-
laxis included only cyclosporine A, without methotrexate. Supportive
therapy and posttransplantation use of hematopoietic growth factors were
in accordance with the policy of each individual center.
Deﬁnition of Endpoints
The primary study endpoints were TFS, graft failure, and overall survival
(OS). TFS was deﬁned as survival without graft failure or a second trans-
plantation. Graft failure was clinically deﬁned as persistent pancytopenia
with no hematological recovery or recurrent thalassemia with relapse of
transfusion dependence. Chimerism data were incomplete and when
available were captured by different techniques over time (eg, globin chain
synthesis, YO chromosome hybridization, analysis of variable number
tandem repeat polymorphisms, microsatellite analysis). For analysis of OS,
failure was deﬁned as death from any cause, and surviving patients were
censored at the date of last contact.
Statistical Analyses
Percentages derived from univariate analysis were compared using the
c2 test or Fisher exact test for dichotomous variables and Pearson’s exact c2
test for qualitative variables of more than 2 categories. For continuous
variables, medians were calculated and compared using the nonparametric
Mann-Whitney U test.
Univariate probabilities of OS and TFS were calculated using the Kaplan-
Meier estimator, and their 95% conﬁdence intervals (CIs) were constructed
using arcsine-transformed intervals. For actuarial probability of graft failure,
the 95% CI of a cumulative terminating event was constructed using log-log
approach. The log-rank test was used to compare survival probabilities.
The impact of the following variables on TFS, graft failure, and OS were
examined: (1) recipient-related factors (age, sex, and pretransplantation
CMV status); (2) disease-related factors (Pesaro risk class, splenectomy); (3)
donor-related factors (sex mismatch, thalassemia status); and (4) trans-
plantation-related factors (graft source [bone marrow, cord blood, or
peripheral blood stem cells], type of transplant [MSD or others], type of
conditioning [busulfan þ cyclophosphamide, irradiation, ﬂudarabine], use
of ATG, and year of transplantation [before or after April 1994, the median
date of HSCT in this study]).
Multivariate Cox proportional hazards regressionwas performed for the
variables that were identiﬁed as associated with one of the endpoints or
were marginally signiﬁcant (P < .10) on univariate analysis, or that had
clinical relevance (ie, age). Logistic regression was used for multivariate
analysis of graft failure.
For all tests, P values were 2-sided, and statistical signiﬁcance was
deﬁned as P < .05. All analyses were done with PASW Statistics version 17.0
(SPSS, Inc., Chicago, IL).RESULTS
OS, TFS, and Status at Last Follow-Up
Actuarial 15-year OS and TFS were 86.8% (95% CI, 80.1%-
92.3%) and 69.4% (95% CI, 63.3%-75.2%), respectively
(Figure 1). Twenty-four patients experienced graft failure
after ﬁrst HSCT, and 13 patients died. The primary causes of
death were GVHD (n ¼ 4), multiorgan failure (n ¼ 2), CMV
pneumonitis (n ¼ 2), neurotoxicity (n ¼ 1), gram-negative
sepsis in a splenectomized patient (n ¼ 1), secondary
hemochromatosis after graft failure (n ¼ 1), and primary
graft failure after ﬁrst allograft (n ¼ 1) or second allograft
(n ¼ 1). All deaths occurred during the ﬁrst 2 years post-
transplantation except for 1 death due to cardiac iron over-
load occurring 13.7 years after graft failure.
At the time of this report, of the remaining 95 patients,
with a median follow-up duration of 12 years, 81 are alive
and free of thalassemia (75 after ﬁrst HSCT, 6 after second
HSCT) and 14 have transfusion-dependent anemia. Eight
patients (3 patients with graft failure and 5 successfully
transplanted) were lost to follow-up after at least 2 years
posttransplantation. The overall proportion of patients with
TFS increased to 75% when second HSCTs were taken into
account.
The results of univariate and multivariate analyses are
presented in Tables 2-5. Pesaro risk classiﬁcation, despite its
approximate use in our report, had a signiﬁcant association
with OS and TFS in both univariate andmultivariate analyses.
On univariate analysis, the OS was signiﬁcantly worse for
adults (63.6% for the 11 adult patients).
Type of donor had a signiﬁcant association with TFS,
greater for recipients of an MSD graft (74%) than for recipi-
ents of other donor grafts (33%), with 3 of 6 patients and 1 of
6 patients alive without thalassemia after a URD transplant
and a familial matched related (other than MSD) transplant,
respectively. The 9 patients who received a cord blood
transplant, all from an MSD, are alive and cured. Stem cell
Table 3
Univariate Analysis of Graft Failure after First Transplantation
Number
of Events
% (95% CI)* P Value
Year of transplantation <.001
1985-1994 20 37.0 (24.2-49.8)
1994-2007 4 7.4 (0.5-13.3)
Age at transplantation .35
2 years 5 33.3 (9.5-57.1)
2-8 years 18 22 (13.1-30.9)
18 years 1 9.1 (0.5-43)
Splenectomy .09
Yes 2 7.4 (1.3-25.8)
No 19 24.4 (14.9-33.9)
Type of transplant .134
MSD 19 19.8 (11.9-27.7)
Other 5 41.7 (13.9-69.5)
Donor thalassemia status .38
Heterozygote 9 17.6 (7.2-28)
Thalassemia-free 11 25 (12.8-37.2)
Recipient CMV status .027
Positive 20 26.7 (16.7-36.7)
Negative 2 6.9 (1.2-24)
Pesaro class .326
1 3 13.6 (3.6-40)
1 or 2 6 25 (7.7-42.3)
2 10 20.4 (9.2-31.6)
2 or 3 4 50 (17.5-82.6)
3 1 20 (1.1-70)
Use of ATG .003
Yes 6 10.5 (2.6-18.4)
No 17 34.7 (21.4-48)
* 95% CI including continuity correction for small numbers.
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rejection, likely because of the low number of patients
receiving cord blood transplantation.
The use of ATG and more recent HSCT were signiﬁcantly
associated with better TFS on univariate analysis (TFS of 55%
and 83%, respectively) (Figure 2A and B). These 2 variables
were related as ATG use increased over time; 31% of patients
who underwent HSCT before April 1994 received ATG, versus
74% of those who did so after this date. Only the year of HSCT
remained signiﬁcant in multivariate analysis.
Splenectomy was an independent factor associated with
better TFS. Although older, with a median age of 11.2 years,
the 27 splenectomized patients did not have more advanced
disease or higher serum ferritin levels (Table 6). Of note, noneTable 4
Multivariate Cox Regression Analysis of TFS after First Transplantation
Relative Risk 95% CI P Value
Year of transplantation
1985-1994 1
1994-2007 0.32 0.11-0.93 .036
Age at transplantation 1.02 0.94-1.11 .609
Type of transplant
MSD 1
Other 4.21 1.54-11.6 .005
Use of ATG
No 1
Yes 0.5 0.10-1.31 .162
Splenectomy
No 1
Yes 0.12 0.03-0.57 .007
Pesaro class .004
1 1
1 or 2 1.27 0.35-4.57 .72
2 1.19 0.35-4.05 .78
2 or 3 18.28 3.11-107 .001
3 4.46 0.65-30.4 .127of the 15 patients age 2 years was splenectomized, and TFS
was poor in this age group (5 graft failures and 2 deaths).
Graft Failure and Second Transplantation
Graft failure after the ﬁrst transplantation (primary
graft failure in 8 cases and rejection or secondary thalas-
semia in 16 cases) was observed in 24 patients, corre-
sponding to a 15-year probability of 23.4% (95% CI,
22.4%-25.2%). Eleven patients underwent a second allogeneic
transplantation: 6 were successfully treated, 2 died, and 3
remained transfusion-dependent. The median interval
between the ﬁrst HSCT and second HSCT was 2 years (range,
1 month to 11 years).
Onunivariate analysis, a signiﬁcant difference in the risk of
graft failure was observed according to date of trans-
plantation, useofATG, and recipientCMVstatus. Splenectomy
before transplantation was nearly statistically signiﬁcant
(P ¼ .07). On multivariate analysis, only recipient CMV status
retained statistical signiﬁcance. Donor thalassemia status,
recipient sex, donorerecipient sex mismatch, stem cell
source, and type of conditioning had no signiﬁcant impact on
any of the 3 primary study endpoints.
GVHD and Veno-Occlusive Disease
Grade II-IV acute GVHD occurred in 22 patients and was
lethal in 2 patients, both of whom received an MSD trans-
plant. Chronic GVHD occurred in 12 patients (limited in 6,
extensive in 6, and lethal in 2, [1 after an URD HSCT and the 1
after a matched related donor HSCT]). The use of ATG had no
apparent association with the risk of acute GVHD (data not
shown). Fourteen patients developed hepatic veno-occlusive
disease after ﬁrst HSCT, but only 1 patient died of this
complication.
DISCUSSION
In this study, we retrospectively analyzed all patients who
underwent HSCT for beta-TM in France between December
1985 (when the ﬁrst transplantation was registered) and
December 2007. This national multicenter study was
exhaustive and reﬂected the global results of this treatment
modality in France. Our median follow-up of 12 years (range,
2-21 years) is one of the longest reported to date. HSCT was
performed quite early in childhood, with a median age at
transplantation of 6.2 years for the 108 patients, but was
rarely proposed to adults, with only 11 undergoing HSCT.
Transplant procedures were generally standard, with the
vast majority of patients receiving bone marrow from an
HLA-identical MSD and a myeloablative conditioning
regimen including busulfan and cyclophosphamide. Given
that only 350 persons with beta-TM (including HSCT recipi-
ents) are listed in the French thalassemia registry, allogeneic
HSCT has been considered as an option for most children
with an MSD [13].
In contrast, URD HSCT was rarely performed and was
associated with poor outcome. Although donor selection
based on stringent compatibility criteria has increased the
probability of TFS in some studies, URD HSCT is associated
with signiﬁcant risk of GVHD [14]. Thus, French trans-
plantation guidelines for thalassemia call for consideration of
URD HSCT only in extreme situations, such as alloimmuni-
zation precluding transfusion.
Considering the large number of involved transplantation
centers (n¼ 21) and the long observation time (more than 20
years), patient survival was good. Actuarial 15-year OS was
86.8% with a median follow-up of 12 years in survivors.
Table 5
Logistic Regression Analysis of Graft Failure after First Transplantation
Odds Ratio 95% CI P Value
Year of transplantation
1985-1994 1
1994-2007 0.21 0.04-1.19 .078
Age at transplantation 0.84 0.68-1.04 .098
Type of transplant
MSD 1
Other 2.44 0.34-17.7 .38
Use of ATG
No 1
Yes 0.19 0.03-1.14 .07
Splenectomy
No 1
Yes 0.14 0.01-1.35 .089
Pesaro class 0.40-30.2 .06
Recipient CMV status
Negative 1
Positive 17.23 2.42-122 .004
Figure 2. Comparative actuarial 15-year probability of TFS after ﬁrst HSCT.
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which occurred in 23% of cases. The incidence of graft failure
was particularly high in HSCTs performed before 1994,
reaching 38%. As a result, intensiﬁed immunosuppression
with the addition of ATG to pretransplantationmyeloablative
conditioning regimens became increasingly popular over
time. In HSCTs performed after 1994, with the more frequent
use of ATG, the incidence of graft failure decreased to 7% and
TFS improved, reaching similar values as those recently re-
ported in Italy and elsewhere (Figure 2A and B) [11,15,16].
Surprisingly, even in the Pesaro class 1 or 2 low trans-
plantation risk group, without ATG, our results were far
worse (graft failure rate of 29%; 11 of 38 patients) than those
obtained by the Italian group, who reported a rejection rate
of only 8% after MSD HSCT during the same time period [4].
Interestingly, in our experience, with the addition of ATG,
graft failure rate decreased signiﬁcantly to 7% in these low-
risk patients (3 of 46 patients; P ¼ .012). Examination of the
role of ATG in reducing graft failure is limited by the global
improvement in supportive care over the study period, as
well as other changes in transplantation procedures, such as
the introduction of i.v. busulfan and pharmacokinetic
busulfan monitoring. Because the present study was retro-
spective and involved a large number of participating
centers, we do not know precisely how often busulfan levels
were monitored and cannot determine the impact of phar-
macokinetic monitoring on transplantation endpoints.
According to the Italian group, the addition of ATG is
recommended only for high-risk transplantations (class 3
children, adults, URD HSCT, or second HSCT) and is not
required for class 1 or 2 recipients of MSD HSCT [14,17-20].
We are not the ﬁrst group to report such a high incidence of
graft failure, however, even in the low transplant risk
group. Outside Italy, numerous studies have investigated the
use of immunosuppressive agents, including ATG and
Campath1G, in addition to the busulfan/cyclophosphamide
conditioning regimen to reduce the incidence of graft
rejection [6,7,9,11]. Interestingly, for sickle cell disease,
another hemoglobinopathy, the use of ATG has proven
successful in reducing graft rejection, and the most experi-
enced French group now recommends ATG in addition to
myeloablative conditioning [21].
A possible explanation for the high rejection rate
observed in the present study is suboptimal medical care of
this rare disease before HSCT. Obviously, pretransplantation
evaluation was insufﬁcient, given that few patients wereaccurately assigned to 1 of the 3 Pesaro risk categories. Given
the missing data and lack of systematic liver histological
evaluation, we applied an approximate stratiﬁcation. Of note,
the value of the Pesaro classiﬁcation is well illustrated in our
experience. Despite an approximate use, the classiﬁcation
remained signiﬁcantly associated with transplantation
outcomes, illustrating the critical importance of quality
medical care before HSCT.
Expanded erythropoietic marrow and splenomegaly have
been invoked to explain the increased rate of rejection/
disease recurrence in patients with beta-TM. Preconditioning
implementation of the transfusion regimen to ablate
expanding thalassemic marrow might be a key factor in
reducing the risk of graft rejection. Whereas pretransfusion
hemoglobin levels are usually maintained at >9-10 g/dL in
experimented Italian centers, the transfusion schemes used
in France aremore variable, with baseline hemoglobin values
often below 9 g/dL [22-24]. Because these levels have been
associated with insufﬁcient inhibition of erythroid marrow
expansion, we believe that suboptimal transfusion might
have contributed to the high rejection rate initially observed
in the French experience [23]. Current French guidelines use
a transfusion scheme based on themaintenance of minimum
pretransfusion hemoglobin >10 g/dL starting at 3-6 months
before conditioning [25].
Table 6
Baseline Characteristics in Patients with and without Pretransplantation
Splenectomy
Splenectomy
(n ¼ 27)*
No
Splenectomy
(n ¼ 78)*
P
Value
Median ferritin level, ng/mL 925 1546 .269
Median age, years 11.2 4.9 <.001
Age 2 years, n 0 15 .02
Median nucleated cell
dose,  108/kg
3.26 3.3 NS
Pesaro class 2-3 or 3, n 4/27 7/78 NS
HSCT before 1994, n 14/27 37/78 NS
Use of ATG, n 16/27 40/77 NS
Recipient CMVþ status, n 21/27 51/74 NS
NS indicates not signiﬁcant.
* Data on splenectomy were not available for 3 patients.
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were identiﬁed: use of an MSD, year of HSCT, Pesaro classi-
ﬁcation, and splenectomy (Tables 3 and 4). Surprisingly, the
observed effect of splenectomy was independent. Although
older (median age, 11.2 years), the 27 splenectomized
patients had a better TFS than the nonsplenectomized
patients. A possible explanation for this ﬁnding is that sple-
nectomy reﬂects better medical care of the disease before
HSCT rather than an advanced stage of the disease. Indeed,
there were no more class 2 or 3 patients in the group of
splenectomized patients, and their median serum ferritin
valuewas<1000 ng/mL. In one study analyzing the impact of
splenectomy on transplantation outcomes, patients who
underwent splenctomy before transplantation exhibited
faster neutrophil recovery, suggesting that splenomegaly
could have a potential adverse impact on engraftment,
through sequestration of infused cells [26]. Although the
beneﬁt of pretransplantation splenectomy remains unclear,
the increased risk of infection associated with this procedure
argues against its use. Finally, in the present study, very
young age was associated with a TFS of only 53%; 7 of the 15
patients age 2 years experienced graft rejection (n ¼ 5) or
died (n ¼ 2). No infants were splenectomized. Our experi-
ence is not isolated, however; Lucarelli et al. [27] also re-
ported poorer outcomes in young children. Consequently,
since 2003, the Italian group has applied more intensive
conditioning (thiotepa 10 mg/kg/day in addition to the
standard busulfan þ cyclophosphamide) for children age <4
years [27]. The reason for this increased rejection rate is
unclear, but it might be explained by the greater variability in
busulfan kinetics in low-weight infants, even with i.v.
formulations or by undertransfusion. Our results suggest that
delaying HSCT until the child is at least 2 years old is
a reasonable approach, to allow efﬁcient suppression of
thalassemic hematopoiesis by regular transfusion and avoid
poor busulfan kinetics.
Considering rejection, only recipient CMVþ status was
independently associated with a higher rate of graft failure
(P ¼ .004; Tables 4 and 5), with ATG not a signiﬁcantly inde-
pendent risk factor for rejection (P ¼ .07). Previous data have
shown that CMV inhibits the engraftment of the transplanted
hematopoietic cells and can cause complete graft failure.
CMV infection itself as well as its antiviral treatment may
jeopardize engraftment and interfere directly with the ther-
apeutic aimofHSCT [28]. In the present cohort study, 2 deaths
were attributed to CMV infection, but because of the retro-
spective nature of this analysis and the long observation time,
evaluating the incidence of CMV reactivation was notpossible. A recent study of 75 thalassemic children who
underwent HSCT with ATG as part of the myeloablative
conditioning regimen reported a 29% rate of CMV reac-
tivation, but no CMV disease [12]. Interestingly, this high rate
of CMV reactivation did not jeopardize the success of bone
marrow engraftment; both transplantation-relatedmortality
and graft failure rate were only 4% for the entire cohort.
In the present study, 22 patients developed grade II-IV
acute GVHD, an incidence rate similar to that reported by
others [29]. The rate of infectious complications, including
bacterial sepsis and CMV disease, was low, as was the rate
of VOD.
Several recent changes in transplantation proceduresmay
further improve outcomes in patients with beta-TM [30-35].
Because our analysis stopped in December 2007, most of our
patients had received oral busulfan, which has since been
replaced by i.v. busulfan with drug monitoring, allowing
dosage adjustment and limiting toxicity [33-36]. In our
experience, as in a recent study, related cord blood trans-
plantationwas associated with very good outcomes. Because
of more systematic cord blood preservation in families with
a thalassemic child, related cord blood transplantation is
expected to become increasingly popular [15,30].
These national results conﬁrm that MSD HSCT is an
effective therapeutic option for beta-TM. Current French
national guidelines recommend HLA-matched identical
sibling HSCT early in the course of the disease and consider
myeloablative conditioning including ATG as a standard of
care, even for low-risk patients. We believe that special
attention should be paid to quality of care before trans-
plantation, and that optimization of both the chelation
regimen and the transfusion program to sufﬁciently suppress
erythropoiesis is crucial before conditioning. The decision to
recommend ATG in addition to a myeloablative regimenwas
based on the balance between the increased risk of infection
associated with intensiﬁed immunosuppression and the
greater risk of marrow rejection without ATG. In hemoglo-
binopathies, recent studies including ATG as part of the
preparative regimen and systematic monitoring for viral
infection to allow preemptive treatment seem to provide
excellent results [12,21]. With the dissemination of the
recent French national guidelines for transplantation in
patients with beta-TM, better knowledge of this rare disease
by hematology and transplant teams in our country should
contribute to improved disease evaluation and patient
preparation before transplantation.
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